The second generation of treatment for schizophrenia and other psychotic disorders offers fewer side effects, but costs are much higher
Get the latest industry news, event updates, and more from Managed healthcare Executive.
A Conversation With IQVIA's Luke Greenwalt, MBA
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
Listen
Upended: Can PBM Transparency Succeed?
Nancy Lurker of EyePoint Pharmaceuticals Addresses Innovations in Eye Care, How to Grow in the C-Suite and What it Takes to Run a Biopharma Company
Change Healthcare Outage Prompts Switch in Pharmacy Claims Processing, Cranks Up Tensions Between Independent Pharmacies and PBMs
UnitedHealth Group Unplugs Change Healthcare Information Systems To Contain Cyberattack